Table 3.
Description of medicines classes with shortages in the selected countries.
| Region/country* | Nervous system | Cardiovascular system | Anti-infectives systemic use | Cancer | Genitourinary system and sex hormones | Alimentary track and metabolism |
|---|---|---|---|---|---|---|
| South America 2017 | 17% | 9% | 21% | 10% | 7% | Non available |
| Belgium 2009–2013 | 23% | 21% | 11% | 9% | Non available | 8% |
| Israel 2013–2015 | 21% | 15% | 16% | Non available | 8% | 7% |
| US 2013–2017 | 18% | 11% | Non available | 9% | Non available | Non available |
| Canada (Videau et al., 2019) | 31.8% | 21.9% | 8.5% | 5.1% | Non available | 0.1% |
| Australia (The Society of Hospital Pharmacists of Australian, SHPA, 2017) | 12% (Anaesthetics) 9% (Neurology) |
10% | 20% | 9.5% | 10% | Non available |
| China (Yang et al., 2016) | 13% | 6% | 6% | 5.7% | 11% | 9% |